医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

RapidAI Enhancing Stroke Care Across Australia

2021年01月21日 PM11:00
このエントリーをはてなブックマークに追加


 

SAN MATEO, Calif.

RapidAI, the leader in advanced imaging for stroke, today announced it now serves over 50 hospitals and teleradiology services in Australia. The Rapid stroke imaging platform is TGA cleared.

Rapid is the first AI-powered stroke imaging solution approved in Australia. Around the world, Rapid is also the only clinically validated platform available and the gold standard for advanced cerebrovascular imaging and workflow.

In addition to broad adoption across the country, Rapid is also being rolled out across the state of New South Wales (NSW). In NSW, Rapid is part of a comprehensive telehealth initiative which leverages the Rapid Mobile App to optimize workflow, communication, and expedite patient treatment throughout the state’s large comprehensive and regional community hospitals.

Along with wide commercial success, RapidAI also continues to drive the research charge in Australia. The company is developing industry leading cerebrovascular imaging solutions through participation in clinical trials with 8 leading Australian hospitals and institutions.

“It has been gratifying to bring RapidAI technology home to support Australian healthcare,” said Doctor Roland Bammer, Professor of Radiology and Director of the NHMRC Centre for Research Excellence in Neuroimaging at the University of Melbourne, Cofounder and CTO at RapidAI. “We have a long-standing research collaboration with Australian Stroke researchers and it is great to see this translated into clinical routine. Australia is a vast country and I am delighted to see more people having access to faster care irrespective of their postcode.”

Doctor Bammer continued, “The statewide adoption in NSW alone has shown the true potential of network coordinated AI-powered stroke imaging and the resulting improvement in care. I am also excited that Monash Health, one of the largest hospital systems in Victoria, is now using Rapid. With its catchment area in the South Eastern Melbourne Metropolitan corridor, the institution reaches over two million Victorians. Access to the Rapid platform will have a considerable positive impact on the Acute Stroke care continuum for the Monash team and its patients.”

RapidAI makes the most-widely used advanced cerebrovascular imaging products for patient care, research, and clinical trials across the globe. RapidAI clinical products help save lives, RapidAI workflow and messaging technologies help stroke teams save time, and RapidAI analytics and business intelligence products help stroke networks reduce costs and improve patient outcomes.

To learn more visit www.RapidAI.com.

About RapidAI

RapidAI is the worldwide leader in advanced imaging for stroke. Based on intelligence gained from over 1,000,000 scans from more than 1,600 hospitals in over 60 countries, the Rapid® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview®, a comprehensive aneurysm management platform.

RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically-proven, data-driven technology. With our validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day. For more information, visit RapidAI.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005088/en/

CONTACT

Peter Evers

Natron Communications for RapidAI

(415) 524-8899

pr@RapidAI.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists